Rep. Gilbert Ray Cisneros, Jr. Sells Shares of Revvity Inc. (NYSE:RVTY)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Revvity Inc. (NYSE:RVTY). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $15,001 and $50,000 in Revvity stock on September 9th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Revvity Price Performance

Shares of RVTY traded down $1.61 on Wednesday, reaching $153.47. The stock had a trading volume of 595,948 shares, compared to its average volume of 1,500,820. The firm has a 50-day moving average of $134.17 and a 200 day moving average of $112.19. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $17.13 billion, a PE ratio of 73.03, a PEG ratio of 2.83 and a beta of 1.06. Revvity Inc. has a twelve month low of $81.22 and a twelve month high of $166.25.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The business had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. During the same period in the previous year, the firm posted $1.18 earnings per share. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts expect that Revvity Inc. will post 5.36 EPS for the current year.

Revvity Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s dividend payout ratio (DPR) is presently 13.33%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on RVTY shares. Barclays boosted their price objective on Revvity from $115.00 to $160.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. William Blair began coverage on shares of Revvity in a research note on Monday, October 5th. They set an “outperform” rating for the company. Royal Bank Of Canada initiated coverage on shares of Revvity in a research report on Tuesday, September 1st. They issued a “sector perform” rating and a $135.00 price target on the stock. Sanford C. Bernstein started coverage on shares of Revvity in a report on Friday, June 26th. They set a “market perform” rating and a $115.00 price objective on the stock. Finally, UBS Group initiated coverage on Revvity in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $140.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $124.43.

Hedge Funds Weigh In On Revvity

Hedge funds have recently made changes to their positions in the stock. Jupiter Topco LLC bought a new position in Revvity during the 2nd quarter worth approximately $961,017,000. BlackRock Inc. bought a new stake in Revvity during the 2nd quarter valued at approximately $852,070,000. Janus Henderson Group PLC lifted its position in shares of Revvity by 7.0% in the 4th quarter. Janus Henderson Group PLC now owns 8,161,171 shares of the company’s stock worth $789,595,000 after acquiring an additional 533,912 shares during the period. EdgePoint Investment Group Inc. grew its stake in shares of Revvity by 3.1% in the 1st quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company’s stock valued at $771,044,000 after purchasing an additional 265,204 shares during the period. Finally, State Street Corp grew its holdings in shares of Revvity by 0.8% in the 2nd quarter. State Street Corp now owns 4,342,739 shares of the company’s stock worth $483,173,000 after purchasing an additional 32,426 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Insider Buying and Selling at Revvity

In other news, insider Tajinder S. Vohra sold 7,330 shares of the business’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the transaction, the insider owned 6,635 shares of the company’s stock, valued at approximately $934,738.80. The trade was a 52.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of Revvity stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the transaction, the insider directly owned 14,781 shares of the company’s stock, valued at approximately $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 9,130 shares of company stock valued at $1,290,745. Corporate insiders own 0.85% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Revvity

Revvity, Inc (NYSE:RVTY) is a life sciences and diagnostics company that provides technologies, products and services used in biological research, drug discovery, clinical testing and healthcare. The company serves pharmaceutical and biotechnology companies, academic and government research institutions, hospitals, clinical laboratories and other healthcare organizations.

Its portfolio includes instruments, reagents, consumables, software and related services for areas such as genomics, proteomics, cellular analysis, imaging and multiplex testing.